From DCAT Value Chain Insights (VCI)
Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo (54) was appointed to the Executive Board to take over leadership for the Pharma business. The management changes will become effective as of January 1, 2015.
Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman of the Executive Board. Both will share strategic management functions and will represent the company with politicians and international organizations
As a member of the Executive Board, Garijo, currently CEO of Merck’s biopharmaceutical division, will take on responsibility for the whole Pharma business. Besides the biopharmaceutical division, this includes consumer health, allergy and biosimilars.
Source: Merck KGaA
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription